Profile
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 5 (2020), Article ID 5:IJCPP-146, 6 pages
https://doi.org/10.15344/2456-3501/2020/146
Original Article
Awareness of Rapid-onset Opioid Formulations among Healthcare Professionals with Experience in Palliative Care: A Questionnaire Survey

Eiji Kose*,1, Taesong An2, Akihiko Kikkawa2 and NobuhiroYasuno1,3

1Department of Pharmacy, Teikyo University School of Medicine University Hospital, 2-11-1 Kaga, Itabashi-ku, Tokyo 274-8555, Japan
2Department of Pharmacy, Yokosuka Kyousai Hospital, 1-16 Yonegahamadohri, Yokosuka-shi, Kanagawa 238-8588, Japan
3Laboratory of Hospital Pharmacy, School of Pharmacy, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 274-8555, Japan
Dr. Eiji Kose, Department of Pharmacy, Teikyo University School of Medicine University Hospital 2-11-1 Kaga, Itabashi-ku, Tokyo 274-8555, Japan, Phone No: +81-3-3964-1211, Fax No: +81-3-3964-9426; E-mail: kose.eiji@med.teikyo-u.ac.jp
01 April 2020; 26 May 2020; 28 May 2020
Kose E, An T, Kikkawa A, Yasuno N (2020) Awareness of Rapid-onset Opioid Formulations among Healthcare Professionals with Experience in Palliative Care: A Questionnaire Survey. Int J Clin Pharmacol Pharmacother 5: 146. doi: https://doi.org/10.15344/2456-3501/2020/146

References

  1. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, et al. (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13: 331-338. View
  2. Boceta J, De la Torre A, Samper D, Farto M, Sánchez-de la Rosa R (2016) Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study. Clin Transl Oncol 18: 1088- 1097. View
  3. Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, et al (2006) Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 7: 583-591. View
  4. Watanabe N, Hosokawa S, Yamada T, Yoshida C, Suzuki A, et al (2017) A Survey of the Current Status of Fentanyl Sublingual Tablets and Evaluation of Problems Associated with Their Proper Use. Journal of Japan Primary Care Association 40: 27-32. View
  5. Fujihara H, Koinuma M, Yumoto T, Maeda T, Kamite M, et al (2015) Expected Duties of Pharmacists and Potential Needs of Physicians and Nurses on a Kaifukuki Rehabilitation Ward. Yakugaku Zasshi 135: 969-975. View
  6. Twycross R, Prommer EE, Mihalyo M, Wilcock A (2012) Fentanyl (Transmucosal). J Pain Symptom Manage 44: 131-149. View
  7. Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81: 129-134. View
  8. Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, et al. (2004) Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18: 177-183. View
  9. Zeppetella G, O'Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20: 87-92. View
  10. Davies A, Zeppetella G, Andersen S, Damkier A, Vejlgaard T, et al (2011) Multicenter European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 15: 756-763. View
  11. Payne R (2007) Recognition and diagnosis of breakthrough pain. Pain Med 8: 3-7. View
  12. McCarberg BH (2007) The treatment of breakthrough pain. Pain Med 8: 8-13. View